SYRS (Syros Pharmaceuticals) Short-Term Debt: $0.00 Mil (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SYRS Syros Pharmaceuticals Inc SYRS
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals Short-Term Debt?

Syros Pharmaceuticals SYRS 12 Short-Term Debt is $0.00 Mil as of Sep. 2024. GuruFocus rates SYRS with a GF Score™ of 12/100.

Syros Pharmaceuticals's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

Syros Pharmaceuticals's quarterly Short-Term Debt declined from Mar. 2024 ($11.67 Mil) to Jun. 2024 ($0.00 Mil) but then stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).

Syros Pharmaceuticals's annual Short-Term Debt stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($6.67 Mil).

Syros Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Syros Pharmaceuticals Short-Term Debt Related Terms

Syros Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Syros Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals Short-Term Debt Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 6.67

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 6.67 11.67 0.00 0.00
SYRS
12GF Score
Syros Pharmaceuticals Inc SYRS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Syros Pharmaceuticals (SYRS) has a Short-Term Debt of $0.00 Mil as of Sep. 2024.
Is Syros Pharmaceuticals' Short-Term Debt too high?
Syros Pharmaceuticals' current Short-Term Debt is $0.00 Mil. Overall, Syros Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Syros Pharmaceuticals' Short-Term Debt compare to AFMDQ and BTAX?
Syros Pharmaceuticals' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Syros Pharmaceuticals's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syros Pharmaceuticals stock overvalued right now?
Syros Pharmaceuticals (SYRS) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Syros Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Syros Pharmaceuticals (SYRS), the current Short-Term Debt is $0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
12GF Score

Get the complete analysis for SYRS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price